Replimune Group, Inc. (REPL)

Replimune Group, Inc. is trading at $15.41, up 5.33% on the session. The 50 day average sits at $10.61 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 67.5, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $11.42 with resistance near $15.71, so that band frames the current range. Average daily movement is roughly $1.50, or about 9.7% of the share price, which is what any stop placement has to allow for. The overall health score of 65 out of 100 combines a trend score of 75, momentum of 88 and a risk score of 16.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.